Loading, Please Wait...
SAN DIEGO, March 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang, Ph.D., President and Chief Operating Officer, and Bill Plovanic, Chief Financial Officer of Obalon, will participate in the following upcoming investor conference:
31st Annual ROTH Conference
Tuesday, March 19, 2019, Presentation at 2:30pm PT
Ritz Carlton, Laguna Niguel in Orange County, CA
Webcast Available at: http://wsw.com/webcast/roth33/obln/
Live audio webcast of the presentation can be accessed through the link above. Replays of the webcast will be available for 90 days following the presentation.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ: OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit http://www.obalon.com/.
For Obalon Therapeutics, Inc.
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103